KCNK2 and depressive symptom measurement: Until now, TREK-1 has been viewed as a novel antidepressant target, because TREK-1 activity is inhibited by antidepressants and the deletion of TREK-1 (KCNK2−/−) resulted in antidepressant-like behavior in models of depression [3,5].